SSRI and psychedelics: Difference between revisions

From BurnZero
No edit summary
mNo edit summary
Line 1: Line 1:
It is thought that if psychedelics are used with SSRIs such as fluoxetine this may lead to [[serotonin]] syndrome and a decrease in subjective [[Psychedelics|psychedelic]] effects. However, this is theoretical and there is no empirical data on the interaction between psychedelics and antidepressants. Recently, the serotonin theory of depression has been cast into doubt by large studies<ref>“No convincing evidence”. BMJ 2022; 378 doi: <nowiki>https://doi.org/10.1136/bmj.o1808</nowiki> (Published 20 July 2022) BMJ 2022;378:o1808</ref>, further disproving this theory.
It is thought that if psychedelics are used with SSRIs such as fluoxetine this may lead to [[serotonin]] syndrome and a decrease in subjective [[Psychedelics|psychedelic]] effects. However, this is theoretical and there is no empirical data on the interaction between psychedelics and antidepressants although it is thought to be more pronounced with people taking NMDA. Recently, the serotonin theory of depression has been cast into doubt by large studies<ref>“No convincing evidence”. BMJ 2022; 378 doi: <nowiki>https://doi.org/10.1136/bmj.o1808</nowiki> (Published 20 July 2022) BMJ 2022;378:o1808</ref>, further disproving this theory.
<hr>
<hr>
'''References'''
'''References'''

Revision as of 20:43, 13 December 2022

It is thought that if psychedelics are used with SSRIs such as fluoxetine this may lead to serotonin syndrome and a decrease in subjective psychedelic effects. However, this is theoretical and there is no empirical data on the interaction between psychedelics and antidepressants although it is thought to be more pronounced with people taking NMDA. Recently, the serotonin theory of depression has been cast into doubt by large studies[1], further disproving this theory.


References

  1. “No convincing evidence”. BMJ 2022; 378 doi: https://doi.org/10.1136/bmj.o1808 (Published 20 July 2022) BMJ 2022;378:o1808

Share your opinion